enGene (NASDAQ:ENGN) Sees Large Volume Increase

enGene Holdings Inc. (NASDAQ:ENGN) shares saw an uptick in trading volume on Friday . 96,435 shares traded hands during trading, an increase of 121% from the previous session’s volume of 43,541 shares.The stock last traded at $15.00 and had previously closed at $14.72.

Analyst Upgrades and Downgrades

Several equities research analysts have issued reports on ENGN shares. Leerink Partnrs restated an “outperform” rating on shares of enGene in a report on Tuesday, February 20th. UBS Group began coverage on shares of enGene in a report on Thursday, March 28th. They issued a “buy” rating and a $37.00 price target on the stock. SVB Leerink began coverage on shares of enGene in a report on Tuesday, February 20th. They set an “outperform” rating and a $31.00 price objective for the company. Wells Fargo & Company started coverage on shares of enGene in a research report on Monday. They issued an “overweight” rating and a $30.00 target price for the company. Finally, Morgan Stanley assumed coverage on shares of enGene in a research report on Friday, March 8th. They set an “overweight” rating and a $40.00 price target on the stock. Six investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company presently has a consensus rating of “Buy” and an average price target of $34.40.

enGene Trading Up 5.3 %

The firm has a fifty day simple moving average of $16.21.

Insiders Place Their Bets

In other news, major shareholder De Solidarite Des Travai Fonds sold 47,854 shares of the stock in a transaction that occurred on Monday, April 22nd. The stock was sold at an average price of $15.00, for a total transaction of $717,810.00. Following the sale, the insider now directly owns 3,036,153 shares in the company, valued at approximately $45,542,295. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Hedge Funds Weigh In On enGene

Institutional investors have recently modified their holdings of the company. Fcpm Iii Services B.V. acquired a new position in enGene during the 4th quarter valued at about $80,097,000. Omega Fund Management LLC bought a new stake in shares of enGene during the fourth quarter valued at approximately $10,441,000. BVF Inc. IL acquired a new position in shares of enGene during the fourth quarter worth approximately $20,777,000. Finally, Vivo Capital LLC bought a new position in enGene in the 4th quarter worth approximately $6,264,000. Institutional investors own 64.16% of the company’s stock.

enGene Company Profile

enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin.